Seismic Therapeutic Secures $121 Million in Series B Funding for Advanced Immunology Drug Development
Slice of Healthcare Team
Dec 06, 2023
Key Highlights
- Seismic Therapeutic, Inc., a machine learning immunology company, announces a $121 million Series B financing, led by Bessemer Venture Partners.
- Funding will advance Phase 1 trials for two lead programs: a pan-IgG protease enzyme candidate (S-1117) and a PD-1 agonist antibody candidate (S-4321).
- The Series B financing also aims to expand the company’s pipeline and enhance its machine learning-enabled IMPACT platform for biologics drug discovery.
- Andrew Hedin, MBA, from Bessemer Venture Partners, will join Seismic’s board of directors.
- Jo Viney, Ph.D., Founder, President, and CEO of Seismic Therapeutic, highlights the company’s vision for a new era in immunology drug development.
Source: Business Wire
Notable Quotes
“ Seismic has made impressive achievements in a short time integrating the power of machine learning with its deep drug development expertise to create two differentiated lead programs. each offering a compelling opportunity to address unmet medical needs in autoimmune diseases in a new way." - Andrew Hedin, MBA, Partner at Bessemer Venture Partners ”
“ This financing enables us to continue our momentum and advance both of our exciting lead programs into the clinic. We believe the time is right to harness advances in machine learning to discover the next generation of biologics drugs to improve the lives of patients with autoimmune diseases." - Jo Viney, Ph.D., Founder, President, and CEO at Seismic Therapeutic ”
